Skip to main content

Omada Health, Inc. (OMDA) Receives a Buy from Barclays

Tipranks - Tipranks - Thu Oct 23, 2025

Barclays analyst Saket Kalia maintained a Buy rating on Omada Health, Inc. today and set a price target of $28.00. The company’s shares closed yesterday at $25.12.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Kalia covers the Technology sector, focusing on stocks such as CrowdStrike Holdings, Adobe, and Autodesk. According to TipRanks, Kalia has an average return of 14.3% and a 65.02% success rate on recommended stocks.

Omada Health, Inc. has an analyst consensus of Strong Buy, with a price target consensus of $25.88, representing a 3.03% upside. In a report released on October 13, Morgan Stanley also maintained a Buy rating on the stock with a $30.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

The company has a one-year high of $28.40 and a one-year low of $14.14. Currently, Omada Health, Inc. has an average volume of 434.9K.

Read More on OMDA:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).